Assessment of adherence to, and persistence with, an electromechanical autoinjector for subcutaneous interferon beta-1a injections for multiple sclerosis treatment over 3 years.
Francesco PirasLilian ArnaudEric HenningerMatthew KeiserAndrea SeitzingerDominic JackQuentin Le MasnePublished in: Expert opinion on drug delivery (2023)
People living with MS were highly adherent to use of the RebiSmart® device, with higher persistence generally observed for older and/or male individuals.